The pharmaceutical company, backed by Allergan and Boehringer Ingelheim, raised the cash after $109m of equity funding.

The Johnson & Johnson-backed Switzerland-based protein developer is looking to go public after raising almost $60m in equity funding.

The venture firm would raise the sum, which effectively doubles the expected size of the IPO, if it floats at the mid-point of its range.

Yahoo ended up securing $9.5bn in the offering, which broke the record previously held by Agricultural Bank of China.

Pharmaceutical company UCB will buy additional shares in the offering as Dermira, which is also backed by Maruho, seeks to raise funds for product development.

The online fashion brand, backed by Tengelmann, Holtzbrinck and Anders Holch Povlsen, will use the proceeds to support growth.

The China-based e-commerce company established its place at the internet's head table with an IPO set to close at $25bn, showing the value of strategic investment.

The Pharmstandard-backed pharmaceutical company is seeking to raise the cash in an IPO four months after it closed part of a $45m series D round.

The Novartis-backed pharmaceutical company will use the proceeds to fund pivotal tests for its prostate cancer drug.

The cancer drug developer, which counts Novo Nordisk among its shareholders, floated below its range, but issued a larger number of shares than expected.